Stock AnalizIDEAYA Biosciences, Inc. IDYA
Biotechnology: Pharmaceutical Preparations · IPO 2019 · data as of November 13, 2026
IDEAYA Biosciences, Inc. (IDYA) is a healthcare company listed in the US with a market value of about $3.1B. In the twelve months to September 30, 2026 it had revenue of $37M and net income of -$420M, a net margin of -1149.6%.
Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 62% a year, a 5-year average ROIC of -16%.
Score: 1.4 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 9 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $37M | $219M | $7M | $23M | $51M | $28M | $20M | $0 | — | — |
| Net income | -$420M | -$114M | -$274M | -$113M | -$59M | -$50M | -$34M | -$42M | -$34M | -$12M |
| Free cash flow | -$350M | -$73M | -$251M | -$118M | -$91M | -$58M | $55M | -$41M | -$29M | -$14M |
| EPS (diluted) | $-4.49 | $-1.28 | $-3.36 | $-1.96 | $-1.42 | $-1.41 | $-1.40 | $-3.36 | $-35.92 | $-17.06 |
| Net margin | -1149.6% | -52.0% | -3921.1% | -483.0% | -115.2% | -178.1% | -176.6% | — | — | — |
| ROIC | — | -12.0% | -23.9% | -17.0% | -14.0% | -13.0% | -13.6% | -32.6% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 13 analysts is $50.69, 59% above the current price; targets range from $30.00 to $66.00; the consensus rating is “Strong buy”; expected EPS is $-4.77 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does IDEAYA Biosciences pay a dividend?
Not currently.
Is IDEAYA Biosciences a good stock to buy?
We do not give buy or sell advice. IDEAYA Biosciences scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.